Kae Ferber, MD
Geriatric Medicine · Naples, FLNPI 1255384749
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 660 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,780 and has fallen 67.7% since, to $1,222 in 2025. Among geriatric medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 660 payments — averaging $26.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Novo Nordisk$2K
- Boehringer Ingelheim$1K
- Johnson & Johnson$911
- Pfizer$716
- Medtronic$630
- plus $10K from 46 others
What the payments were for
- Food & beverage$17,737100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$617
- WATCHMAN FLX$427
- XARELTO$409
- KRYSTEXXA$373
- Tymlos$351
- Leqembi$348
- Ozempic$345
- JARDIANCE$341
- EVENITY$250
- Kerendia$244
- Wegovy$230
- Endurant$228
- ENDURANT IIS$209
- Inspire Upper Airway Stimulation System$176
- ENROUTE Transcarotid Neuroprotection System$133
- ENROUTE Transcarotid Stent$133
- XIFAXAN$125
- NEXLIZET$125
- NEXLETOL$125
- BREZTRI$125
How this compares
$17,768 in reported general payments places this provider in the 95th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $107,006 |
| EliquisApixaban | 52 | $66,735 |
| OtezlaApremilast | 11 | $50,300 |
| JardianceEmpagliflozin | 33 | $42,577 |
| TymlosAbaloparatide | 12 | $37,164 |
| XareltoRivaroxaban | 26 | $33,390 |
| ProliaDenosumab | 13 | $22,659 |
| JanuviaSitagliptin Phosphate | 14 | $20,539 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $19,240 |
| EntrestoSacubitril/Valsartan | 13 | $14,915 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $12,568 |
| SynthroidLevothyroxine Sodium | 116 | $12,089 |
| MounjaroTirzepatide | 14 | $12,070 |
| Repatha SureclickEvolocumab | 15 | $11,849 |
| RybelsusSemaglutide | 12 | $11,535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,560 | $118,54193 claims |
| AmgenOtezla, Prolia | $3,196 | $72,95924 claims |
| PfizerEliquis | $716 | $66,73552 claims |
| Boehringer IngelheimJardiance | $1,035 | $42,57733 claims |
| Radius Health, Inc.Tymlos | $526 | $37,16412 claims |
| Johnson & JohnsonXarelto | $911 | $33,39026 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $513 | $30,53730 claims |
| MerckJanuvia | $596 | $20,53914 claims |
| NovartisEntresto | $573 | $14,91513 claims |
| AbbVieSynthroid | $369 | $12,089116 claims |
| Lilly USA, LLCMounjaro | $629 | $12,07014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 305 geriatric medicine providers in Florida.
Other geriatric medicine in Naples
- Angel HerreraNaples$12K
- Charina Yango CadavosNaples$3K
- Urooj QaziNaples$2K
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Naushira PandyaDavie$145K
- Rosemary LairdViera$64K
- Jonathan AppelbaumMonticello$59K
- John PotomskiMelbourne$31K
- Valeria Baldivieso HurtadoWinter Park$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.